1. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures

2. Introduction

3. Program Overview

4. Thrombocytopenia: Clinical Significance

5. Factors Influencing the Decision to Treat Thrombocytopenia

6. Factors Influencing the Decision to Treat Thrombocytopenia (cont)

7. Treatment Options for Severe Thrombocytopenia

8. Platelet Transfusion

9. Normal Thrombopoiesis

10. Mechanism of Action of TPO RAs

11. TPO RAs

12. ELEVATE: Median Platelet Counts

13. ELEVATE: Incidence of Portal-Vein or Splanchnic-Vein Thrombosis

14. ELEVATE: Thrombotic Events in Patients Receiving Eltrombopag

15. ADAPT 1 and 2: Mean Platelet Counts

16. L-PLUS-2: Median Platelet Count

17. L-PLUS-2: Efficacy of Lusutrobopag

18. Lusutrombopag Safety: Pooled Analysis of 2 Phase 3 Trials

19. Use of TPO-RAs in Clinical Practice

20. Potential Role of Emerging TPO RAs

21. Program Summary

22. Abbreviations